Informations pratiques

Description de la ressource

Résumé

Non-pharmaceutical medical innovations and public health The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms underlying LSC behavior in TKI-treated patients may provide important clues to develop an array of strategies that ensure the complete destruction of LSC reservoirs and thereby offer CML patients a definitive cure. Cette présentation a été donnée dans le cadre du Scientific BRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunir tous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.

"Domaine(s)" et indice(s) Dewey

• Cancer (616.994)

Domaine(s)

Intervenants

Édition

• Université de Bordeaux - Service Audiovisuel et Multimédia

Diffusion

Cette ressource vous est proposée par :

• Cette ressource fait partie de
  • BRIO SIRIC scientific day 2